Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | GRM1 | Q13255 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.62 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.62 |
| ▸ | KDM1A | O60341 | 4/20 | 0.54 |
| ▸ | RXRA | P19793 | 4/20 | 0.42 |
| ▸ | SRD5A2 | P31213 | 4/20 | 0.41 |
| ▸ | SRD5A1 | P18405 | 3/20 | 0.41 |
| ▸ | RAD52 | P43351 | 1/20 | 0.40 |
| ▸ | RXRB | P28702 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1809924 | 1.00 | KDM4E (1.00) | KDM4EMAPTCYP2C19ALDH1A1POLB | |
| SCHEMBL391979 | 1.00 | KDM4E (1.00) | KDM4EMAPTCYP2C19ALDH1A1POLB | |
| SCHEMBL7405059 | 0.91 | KDM4E (0.83) | KDM4EMAPTCYP2C19ALDH1A1POLB | |
| SCHEMBL7400117 | 0.89 | KDM4E (0.79) | KDM4EMAPTCYP2C19ALDH1A1POLB | |
| SCHEMBL23963695 | 0.82 | KDM4E (0.69) | KDM4EMAPTCYP2C19ALDH1A1POLB | |
| SCHEMBL7403597 | 0.82 | KDM4E (0.69) | KDM4EMAPTCYP2C19ALDH1A1POLB | |
| SCHEMBL17604912 | 0.81 | KDM4E (0.68) | KDM4EMAPTCYP2C19ALDH1A1POLB | |
| SCHEMBL20693656 | 0.81 | KDM4E (0.68) | KDM4EMAPTCYP2C19ALDH1A1POLB | |
| SCHEMBL17605162 | 0.81 | KDM4E (0.68) | KDM4EMAPTCYP2C19ALDH1A1POLB | |
| SCHEMBL29802007 | 0.81 | KDM4E (0.68) | KDM4EMAPTCYP2C19ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200085790-A1 | BACLOFEN AND ACAMPROSATE BASED THERAPY OF NEUROLOGICAL DISORDERS | PHARNEXT (FR) | 2020-03-19 | — | — | US | disclosed |
| US-20170231958-A1 | BACLOFEN AND ACAMPROSATE BASED THERAPY OF NEUROLOGICAL DISORDERS | PHARNEXT S.A. (FR) | 2017-08-17 | — | — | US | disclosed |
| US-9636316-B2 | Baclofen and acamprosate based therapy of neurological disorders | PHARNEXT (FR) | 2017-05-02 | — | — | US | disclosed |
| US-20160000736-A1 | BACLOFEN AND ACAMPROSATE BASED THERAPY OF NEUROLOGICAL DISORDERS | PHARNEXT S.A. (FR) | 2016-01-07 | — | — | US | disclosed |
| US-9144558-B2 | Baclofen and acamprosate based therapy of neurological disorders | PHARNEXT (FR) | 2015-09-29 | — | — | US | disclosed |
| US-20140378440-A1 | BACLOFEN AND ACAMPROSATE BASED THERAPY OF NEUROLOGICAL DISORDERS | PHARNEXT S.A. (FR) | 2014-12-25 | — | — | US | disclosed |
| US-20090209474-A1 | NOVEL USES FOR DRUGS TARGETING GLUTAMINE SYNTHETASE | NEWTHERA (FR) | 2009-08-20 | — | — | US | disclosed |
| US-20090209474-A1 | NOVEL USES FOR DRUGS TARGETING GLUTAMINE SYNTHETASE | NEWTHERA (FR) | 2009-08-20 | — | — | US | disclosed |
| WO-2007017768-A2 | NOVEL USES FOR DRUGS TARGETING GLUTAMINE SYNTHETASE | NEWTHERA (FR) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209474-A1 | NOVEL USES FOR DRUGS TARGETING GLUTAMINE SYNTHETASE | GLUL, GLS2, ASNS | KDM4E 2324/4885MAPT 4237/4885CYP2C19 874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.